Drugs / IMC-3C5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01288989 | Mar 2011 → Jul 2014 | neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMC-3C5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01288989 ↗ |
| Known as | LY3022856 | “Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced...” PMID 27566701 ↗ Aug 2016 |
| Action | Inhibit | “Vascular endothelial growth factor receptor 3 inhibitor” CHEMBL2109602 ↗ |
| Modality | Monoclonal antibody | “VEGFR-3 human immunoglobulin G subclass 1 monoclonal antibody” PMID 27566701 ↗ Aug 2016 |
| Route | Intravenous | “patients treated intravenously at doses of 5-30 mg/kg weekly” PMID 27566701 ↗ Aug 2016 |
| Target | FLT4 | “Vascular endothelial growth factor receptor 3 inhibitor” CHEMBL2109602 ↗ |